BioMarin Pharmaceutical Inc. (BMRN)

In December 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion. In November 2025, the company was scheduled to participate in the Jefferies Global Healthcare Conference. In October 2025, new options contracts began trading, BioMarin reported strong third-quarter results and increased revenue guidance, and Ascendis Pharma A/S filed a patent infringement case against BioMarin. In September 2025, an analyst rated BioMarin's stock as a 'Strong Buy,' projecting a 52% upside. In June 2025, BioMarin presented five-year Phase 3 results for ROCTAVIAN, reinforcing its long-term efficacy and safety. In January 2026, Arpit Davé was appointed as Chief Digital and Information Officer, BioMarin announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, Veeva and BioMarin formed a long-term strategic partnership, TD Cowen maintained a Buy rating with a $120.00 price target, Wedbush noted BioMarin's goal for sustained growth in 2026, Zacks Rank assigned BMRN a #2 (Buy) rating, European regulators revoked a patent for Voxzogo, and the FDA is expected to issue a verdict on Ascendis Pharma's rival therapy by the end of February 2026.

Demand for BioMarin Pharmaceutical's products generally exhibits consistent patterns rather than significant seasonality due to the chronic nature of the conditions treated. Revenue fluctuations might occur due to the timing of large government orders, but this reflects revenue recognition rather than seasonal changes in patient demand. Products like Voxzogo and Palynziq have shown continued high and strong global demand.

BioMarin Pharmaceutical, Inc. is a global biotechnology company focused on developing and commercializing innovative medicines for rare genetic diseases, particularly enzyme replacement therapies. The company translates genetic discoveries into transformative medicines for life-threatening conditions. Its portfolio includes Voxzogo for achondroplasia, Roctavian for severe hemophilia A, Kuvan and Palynziq for phenylketonuria (PKU), Naglazyme for Mucopolysaccharidosis Type VI (MPS VI), Aldurazyme for Mucopolysaccharidosis Type I (MPS I), Vimizim for MPS IVA, and Brineura for late infantile neuronal ceroid lipofuscinosis (CLN2).

BioMarin Pharmaceutical Inc. is headquartered in San Rafael, California, U.S., with offices and facilities across the United States, South America, Asia, and Europe. Its manufacturing operations are located in Novato, California, and Shanbally, Ireland. The company conducts commercial business operations in the US, Europe, Latin America, the Middle East, and Asia-Pacific, with its products reaching patients in approximately 80 countries worldwide.

BioMarin's brand reputation has been shaped by positive developments and ongoing challenges. Positive events include initiating legal action against Ascendis Pharma A/S for patent infringement, affirming victory in a securities class action lawsuit, being recognized as a leader in developing innovative therapies for rare genetic diseases, and being recognized as a Humankind 100 company. Challenges include criticism regarding drug pricing and instances of denying access to drugs in clinical trials, as well as room for improvement concerning Greenhouse Gases and Air Pollution.

BioMarin Pharmaceutical Inc.'s ownership is predominantly held by institutional investors, who collectively own a significant portion of the company's shares, often exceeding 70-80% of outstanding shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., Primecap Management Co/ca/, Dodge & Cox, State Street Corp, Viking Global Investors Lp, Renaissance Technologies LLC, Capital Research Global Investors, and Wellington. Insider ownership typically remains under 2-3%, while individual and retail investors also hold shares.